Pharmaceutical Discovery, R-47B, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-6101, USA. lisa.hasvold@abbott.com
Abstract:
Farnesyltransferase inhibitors (FTIs) have been developed as potential anti-cancer agents due to their efficacy in blocking malignant growth in a variety of murine models of human tumors. To that end, we have developed a series of pyridone farnesyltransferase inhibitors with potent in vitro and cellular activity. The synthesis, SAR and biological properties of these compounds will be discussed.